Gastrointestinal Neoplasms: Clinical Trials

14,491 trials for Gastrointestinal Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5940 completed, 3106 unknown, 2213 recruiting, 1085 terminated. 4455 Phase 2, 3577 Not applicable, 2352 Phase 1, 1334 Phase 3, 254 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 24455Completed 1628, Unknown 943, Recruiting 685, Terminated 451, Not yet recruiting 277, Active not recruiting 275, Withdrawn 162, Suspended 24, Enrolling by invitation 10
Not applicable3577Completed 1521, Unknown 798, Recruiting 546, Not yet recruiting 235, Terminated 183, Active not recruiting 154, Withdrawn 88, Enrolling by invitation 40, Suspended 12
Phase 12352Completed 984, Recruiting 396, Terminated 339, Unknown 268, Active not recruiting 176, Not yet recruiting 89, Withdrawn 77, Suspended 17, Enrolling by invitation 6
Phase 31334Completed 524, Unknown 325, Recruiting 205, Terminated 105, Active not recruiting 82, Not yet recruiting 63, Withdrawn 23, Enrolling by invitation 4, Suspended 3
Phase 4254Completed 125, Unknown 65, Not yet recruiting 21, Recruiting 16, Terminated 16, Withdrawn 6, Active not recruiting 3, Enrolling by invitation 1, Suspended 1
Early Phase 1134Unknown 38, Completed 31, Recruiting 19, Terminated 14, Not yet recruiting 11, Active not recruiting 7, Withdrawn 7, Enrolling by invitation 5, Suspended 2

Follow Gastrointestinal Neoplasms: new trials by email Literature Review of Gastrointestinal Neoplasms trials Research Report on Gastrointestinal Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Neoadjuvant Therapy for Esophageal Cancer
Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy
Not applicableEnrolling by invitationCancer Hospital Chinese Academy of Medical Science, Shenzhen Center432028-03-012025-05-25
Improving Clinic Delivery of HIV-related Anal Health Services
PEACHES 2.0 Implementation Strategies - HIV, Gonorrhea
Not applicableNot yet recruitingAlbert Einstein College of Medicine82028-02-012026-10-13
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp
Phase 2Not yet recruitingVejle Hospital1102028-02-012026-04-30
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer
Phase 2SuspendedHoly Stone Healthcare Co., Ltd1002027-12-012026-09-18
Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer
intravoxel incoherent motion magnetic resonance imaging - Rectal Neoplasms, Prognosis
Not yet recruitingSichuan Cancer Hospital and Research Institute4002027-11-012025-12-08
DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
blood sampling, Blood sampling - Renal Impairment, Digestive Cancers
Not yet recruitingCentre Hospitalier Universitaire de Besancon7422027-10-012026-11-02
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Immunotherapy Treating GI Cancer
engineered immune cells - Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
SGA-OCRC: Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarians With Resectable Colorectal Cancer
Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer
Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine10002027-06-012026-10-29
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)202027-05-252026-09-29
CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Phase 1Not yet recruitingCity of Hope Medical Center362027-05-062026-09-25
PET/MRI in Rectal Cancer
Total Neo-adjuvant Therapy, 18FDG-PET/MRI scan - Rectal Cancer
Phase 2Not yet recruitingAHS Cancer Control Alberta402027-05-012026-10-28
Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options
Liver transplantation - Colorectal Neoplasms, Liver Neoplasms
Not applicableNot yet recruitingCharite University, Berlin, Germany2602027-04-012026-09-10
Cancer Awareness Among Syrian Migrants
PMT-Based Cancer Screening Educational Intervention, PMT-Based Cancer Screening Education Program - Breast Cancer Screening, Cervical Cancer Screening
Not applicableNot yet recruitingToros University302027-03-092026-10-15
Life Expectancy-informed Colorectal Cancer Screening
Decision Tool - Colorectal Cancer Control and Prevention
Not applicableNot yet recruitingKathryn Martinez150002027-03-012026-10-20
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] - Colon Cancer
Phase 2Not yet recruitingJohn Strickler, M.D.242027-03-012026-11-05
Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer
Stereotactic body radiation treatment (SBRT) - Esophageal Cancer
Phase 2Not yet recruitingAHS Cancer Control Alberta222027-03-012026-10-28
Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors
Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor
Phase 2Not yet recruitingJoal Beane592027-02-152026-10-13
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
Dietary Fiber, Enema Administration, Loperamide Hydrochloride - Low Anterior Resection Syndrome, Rectal Carcinoma
Not applicableRecruitingOhio State University Comprehensive Cancer Center802027-02-152026-10-06
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14

Showing 20 of 14491. Sign in to see all of them.

Narrower conditions

Colorectal Neoplasms (6139)  ·  Stomach Neoplasms (3188)  ·  Colonic Neoplasms (2382)  ·  Rectal Neoplasms (2245)  ·  Esophageal Neoplasms (1843)  ·  Breast Neoplasms (1012)  ·  Neoplasms (883)  ·  Pancreatic Neoplasms (803)  ·  Carcinoma, Non-Small-Cell Lung (724)  ·  Lung Neoplasms (690)  ·  Neoplasm Metastasis (653)  ·  Esophageal Squamous Cell Carcinoma (626)  ·  Ovarian Neoplasms (555)  ·  Prostatic Neoplasms (439)

Broader conditions

Digestive System Diseases (14429)  ·  Gastrointestinal Diseases (14410)  ·  Digestive System Neoplasms (14395)  ·  Neoplasms by Site (14188)  ·  Neoplasms (13608)  ·  Intestinal Diseases (9471)  ·  Intestinal Neoplasms (9373)  ·  Rectal Diseases (7940)  ·  Colonic Diseases (7875)  ·  Colorectal Neoplasms (3241)  ·  Stomach Diseases (3201)  ·  Neoplasms by Histologic Type (2549)  ·  Head and Neck Neoplasms (2379)  ·  Esophageal Diseases (2322)

Interventions

Oxaliplatin (1007)  ·  Fluorouracil (960)  ·  Capecitabine (783)  ·  Leucovorin (688)  ·  Irinotecan (633)  ·  Bevacizumab (600)  ·  Cetuximab (429)  ·  Cisplatin (417)  ·  Radiotherapy (385)  ·  Paclitaxel (320)  ·  pembrolizumab (304)  ·  Drug Therapy (247)  ·  Docetaxel (221)  ·  Folfox protocol (194)  ·  Nivolumab (193)

Sponsors

National Cancer Institute (NCI) (316)  ·  Fudan University (257)  ·  Sun Yat-sen University (208)  ·  M.D. Anderson Cancer Center (181)  ·  Memorial Sloan Kettering Cancer Center (168)  ·  Hoffmann-La Roche (118)  ·  Yonsei University (99)  ·  National Taiwan University Hospital (89)  ·  City of Hope Medical Center (85)  ·  Pfizer (81)  ·  Tianjin Medical University Cancer Institute and Hospital (80)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (79)  ·  Samsung Medical Center (76)  ·  Alliance for Clinical Trials in Oncology (73)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (72)

Countries

United States (4353)  ·  China (3355)  ·  France (1067)  ·  South Korea (939)  ·  Spain (791)  ·  Italy (770)  ·  United Kingdom (744)  ·  Germany (672)  ·  Canada (655)  ·  Netherlands (498)  ·  Taiwan (452)  ·  Japan (450)  ·  Belgium (437)  ·  Australia (383)  ·  Denmark (329)

Top investigators

Norman Wolmark, MD (21)  ·  Lin Shen, MD (18)  ·  Ajay Goel, PhD (17)

Results publications

PMID 33538338, PMID 35623069, PMID 26808342, PMID 36306483, PMID 40341124, PMID 15496622, PMID 35588252, PMID 37162250, PMID 30207593, PMID 31268130, PMID 33356421, PMID 40340830, PMID 20728210, PMID 22646630, PMID 26049686, PMID 26187751, PMID 28712102, PMID 30679026, PMID 31378656, PMID 32816630, PMID 36990609, PMID 37934000, PMID 18316791, PMID 19269519, PMID 19339720, PMID 21596621, PMID 21997132, PMID 22070868, PMID 26254683, PMID 30089078, PMID 30274985, PMID 32085892, PMID 32251400, PMID 33657038, PMID 33792646, PMID 36748942, PMID 37310167, PMID 38421211, PMID 38592721, PMID 40341199, PMID 42681563, PMID 15273542, PMID 15894098, PMID 16971718, PMID 17046465, PMID 17976611, PMID 18309943, PMID 20106720, PMID 21684205, PMID 22067400

NIH funding

2023 (87), 2025 (61), 2017 (49), 2019 (48), 2018 (43), 2015 (41), 2016 (41), P30CA033572 (37), 2009 (34), 2014 (31), 2008 (28), P30CA015083 (27), P30CA014089 (25), P30CA016672 (23), U10CA032102 (22)